Roche’s Accu-Chek SmartGuide CGM System Gains CE Mark for Diabetic Patients
Shots:
- Roche’s Accu-Chek SmartGuide CGM system has obtained CE Mark for type 1 & type 2 diabetic patients (18yrs.) on flexible insulin therapy. It will be introduced in the upcoming months
- The system’s efficacy was established in a trial showing a mean absolute relative difference (MARD) of 9.2% & 99.8% in glucose values within zones A & B on the Parkes Error Grid with its predictive features exceeding in accuracy, sensitivity, specificity & event detection
- The system comprises an Accu-Chek SmartGuide CGM sensor, SmartGuide App & SmartGuide Predict App. The sensor sends real-time glucose values to the SmartGuide app and the Predict app identifies patterns, predicts future glucose levels & indicates hypoglycemia risk within 30mins.
Ref: Roche | Image: Roche
Related News:- Roche’s Vabysmo Prefilled Syringe Receives the US FDA’s Approval for Vision Loss
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
